+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women



The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women



Journal of Thrombosis and Haemostasis 4(8): 1701-1706



Clinical trials have demonstrated that oral conjugated equine estrogen (CEE) therapy with or without medroxyprogesterone (MPA) increases venous thrombotic risk but this safety issue has not been investigated for other oral estrogens. Based on observational study findings that esterified estrogen (EE) was not associated with venous thrombotic risk whereas CEE was, we hypothesized that CEE users would be more resistant to activated protein C (APC), a prothrombotic phenotype, than EE users. We conducted an observational, cross-sectional study of postmenopausal women 30-89 years old who were controls in a case-control study of venous thrombosis. Use of CEE, EE, and MPA at the time of phlebotomy was determined using computerized pharmacy records. APC resistance was measured in plasma by the endogenous thrombin potential normalized APC sensitivity ratio. Adjusted mean APC resistance values were compared across estrogen type and CEE:EE ratios are presented. There were 119 CEE and 92 EE users at the time of phlebotomy. Compared with EE users, CEE users had APC resistance measures that were 52% higher (1.52; 95% confidence intervals: 1.07-2.17) in adjusted analyses. Restricting to modal dose users (0.625 mg) and stratifying by MPA use did not materially change associations. CEE use was associated with higher levels of APC resistance when compared with EE use in postmenopausal women. These findings might provide an explanation for the higher risk of venous thromboembolism previously observed with CEE compared with EE use and, if replicated, may have safety implications for women when choosing an estrogen for symptom relief.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 050603253

Download citation: RISBibTeXText

PMID: 16879211

DOI: 10.1111/j.1538-7836.2006.02045.x


Related references

Conjugated equine estrogen, esterified estrogen, prothrombotic variants, and the risk of venous thrombosis in postmenopausal women. Arteriosclerosis, Thrombosis, and Vascular Biology 26(12): 2807-2812, 2006

Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Human Reproduction 21(10): 2715-2720, 2006

Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 106(14): 1771-1776, 2002

Esterified estrogen and conjugated equine estrogen and the risk of incident myocardial infarction and stroke. Archives of Internal Medicine 166(4): 399-404, 2006

Differential Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Acquired Resistance to Activated Protein C among Postmenopausal Women A Randomised Trial. Blood 100(11): Abstract No 1036, November 16, 2002

Combined conjugated esterified estrogen plus methyltestosterone supplementation and risk of breast cancer in postmenopausal women. Maturitas 79(1): 70-76, 2016

Serum lipoprotein effects of conjugated estrogen and a sequential conjugated estrogen-medrogestone regimen in hysterectomized postmenopausal women. American Journal of Obstetrics and Gynecology 160(5 Pt 1): 1128-1134, 1989

Conjugated equine estrogen, raloxifene and arterial stiffness in postmenopausal women. Climacteric 11(5): 390-396, 2008

Effect of conjugated estrogen versus conjugated estrogen associated with medroxyprogesterone acetate in postmenopausal women on internal carotid artery pulsatility index: a randomized pilot study. Journal of Obstetrics and Gynaecology Research 37(7): 815-818, 2012

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291(14): 1701-1712, 2004

Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial. Journal of Clinical Oncology 27(36): 6135-6143, 2010

Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women. Journal of the American College of Cardiology 40(11): 1991-1999, December 4, 2002

Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. Journal of Bone and Mineral Research 21(6): 817-828, 2006

Effects of Conjugated Equine Estrogen on Risk of Fractures and BMD in Postmenopausal Women With Hysterectomy: Results From the Women's Health Initiative Randomized Trial. Yearbook of Endocrinology 2007: 341-342, 2007

The influence of hormone replacement with conjugated equine estrogen or with estradiol on lipid metabolism in postmenopausal women. Maturitas 27(SUPPL ): 102, 1997